Zomedica Corp.

As of June 30, 2026, Zomedica Corp. carries a market capitalization of 95.06M, placing it among publicly traded companies globally. Its enterprise value stands at 52.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zomedica Corp.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Zomedica Corp. has 979.95M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.66, and the price-to-book ratio stands at 0.89.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 52.75M versus a market cap of 95.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zomedica Corp. maintains a current ratio of 6.43, meaning it holds 6.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Zomedica Corp. posted a negative return on equity (ROE) of -16.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.49, reflecting losses generated across the asset base. The company generates approximately 248,667.83 in revenue per employee across its workforce of 143.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.17 indicates how many times Zomedica Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zomedica Corp. recorded an income tax benefit of -137,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -20.36M and -20.23M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Zomedica Corp.'s stock has gained approximately 11.29% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.10.

Over the twelve months ended June 30, 2026, Zomedica Corp. generated 35.75M in revenue and converted that into -20.23M in net income, yielding earnings per share of -0.02. EBITDA reached -14.61M, while operating income came in at -22.18M.

As of June 30, 2026, Zomedica Corp. holds 44.13M in cash and equivalents against 1.83M in total debt, resulting in a net debt position of -7.19M. Total book value stands at 107.28M, with working capital of 48.89M providing operational flexibility.

Zomedica Corp. produced -14.15M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.73M in capital expenditures, free cash flow totaled -15.88M - equivalent to -0.02 per share.

Over the twelve months ended June 30, 2026, Zomedica Corp. posted a gross margin of 65.35, reflecting its pricing power and cost economics. The operating margin of -62.05 and net profit margin of -56.59 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Zomedica Corp. has an Altman Z-Score of 0.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.